Barclays PLC Eledon Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 79,753 shares of ELDN stock, worth $140,365. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,753
Previous 101,878
21.72%
Holding current value
$140,365
Previous $276,000
25.72%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ELDN
# of Institutions
89Shares Held
32.2MCall Options Held
0Put Options Held
360K-
Bvf Inc San Francisco, CA6.29MShares$11.1 Million0.88% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.57MShares$6.28 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$5.75 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY2.07MShares$3.65 Million0.21% of portfolio
-
Zimmer Partners, LP New York, NY1.83MShares$3.21 Million0.13% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $24.2M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...